C4 Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker.
Hepatocellular carcinoma (HCC) is characterized by a high rate of neovascularization, giving tumoral cells access to nutrients and contributing to disease progression and metastasis.
Researchers from the University of Jeddah and Cairo University have reported the discovery of novel anticancer candidates with efficacy in models of colorectal carcinoma.
The role that guanylate binding protein 1 (GBP1) plays in cervical cancer is still controversial. The effects of GBP1 on cervical cancer were investigated by Chinese researchers from the Xinjiang Medical University.
Among the firms updating progress at the J.P. Morgan Healthcare Conference (JPM) in San Francisco this week was Relay Therapeutics Inc., coming off a $30 million financing to boost its Dynamo platform and candidates.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
RSS
